Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Organogenesis HoldingsORGO -3.91%62 Equity-to-Asset is 0.71 as of Jun. 2026, which is 20% above its 10-year median of 0.59. GuruFocus rates ORGO with a GF Score™ of 62/100 and a GF Value™ of $3.04 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Organogenesis Holdings ranks better than 65.97% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Organogenesis Holdings Equity-to-Asset Related Terms
Organogenesis Holdings Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Organogenesis Holdings's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ORGO vs AKBA, TKNO, EBS: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organogenesis Holdings Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Organogenesis Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Organogenesis Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organogenesis Holdings (ORGO) has a Equity-to-Asset of 0.71 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Organogenesis Holdings and its competitors. This is 20% above median its historical median of 0.59. According to the industry distribution chart, Organogenesis Holdings ranks #342 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 34%.
Is Organogenesis Holdings' Equity-to-Asset too high?
Organogenesis Holdings' current Equity-to-Asset of 0.71 is 20% above median its 10-year median of 0.59. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Organogenesis Holdings' value of 0.71 is 16.4% above this industry median. Based on the distribution chart, Organogenesis Holdings ranks #342 out of 1005 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Organogenesis Holdings has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' Equity-to-Asset compare to AKBA and TKNO?
According to the Drug Manufacturers industry distribution chart, Organogenesis Holdings ranks #342 out of 1005 companies for Equity-to-Asset. This puts Organogenesis Holdings in the upper half of its industry. The industry median Equity-to-Asset is 0.61. Organogenesis Holdings' value of 0.71 is 16.4% above this benchmark. While the company's 10-year median is 0.59 vs. the industry median of 0.61, Organogenesis Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organogenesis Holdings's current Equity-to-Asset of 0.71 is 16.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Organogenesis Holdings and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organogenesis Holdings's current Equity-to-Asset is 0.71, which is 20% above median its own 10-year median of 0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (ORGO) is currently considered Possible Value Trap. The stock's GF Value™ is $3.04, compared to a current price of $1.73 — trading 43.3% below its estimated fair value. The current Equity-to-Asset is 0.71, which is 20% above median its 10-year median of 0.59 and 16.4% above the Drug Manufacturers industry median of 0.61. Organogenesis Holdings' overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Organogenesis Holdings (ORGO), the current Equity-to-Asset is 0.71 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organogenesis Holdings (ORGO) Overvalued in 2026?
Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued.
The current stock price of $1.73 is trading 43.3% below its estimated GF Value™ of $3.04.
GuruFocus considers Organogenesis Holdings to be Possible Value Trap.
Key valuation signals for ORGO:
Equity-to-Asset: 0.71 (20% above median its 10-year median of 0.59)
GF Value™: $3.04 vs. price of $1.73 (43.3% below fair value)
Industry Position: 16.4% above the Drug Manufacturers median (#342 of 1005)
No single metric tells the full story. See the ORGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
62GF Score
Get the complete analysis for ORGO
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORGO has been successfully added to your 
